Video

Dr. Brown on Future Directions for Surgery in Ovarian Cancer

Jubilee Brown, MD, discusses future directions for surgery in ovarian cancer.

Jubilee Brown, MD, a professor and associate director of Gynecologic Oncology at the Levine Cancer Institute, of Atrium Health, discusses future directions for surgery in ovarian cancer.

With the possibility of tailoring treatments to individual patients, there is an opportunity to decrease patient morbidities, says Brown. These possibilities could potentially expand the clinical utility of surgery, according to Brown.

If cytoreductive surgery can be used to help patients with recurrent disease while decreasing morbidities, such as colostomies, and to increase quality of life without pain, then patients will greatly benefit, Brown explains. Future directions will be focused on findings ways to decrease morbidity and improve patient outcomes, Brown concludes.

Related Videos
Kathleen N. Moore, MD, MS
Casey M. Cosgrove, MD, gynecologic oncologist, assistant professor, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute
Casey M. Cosgrove, MD, gynecologic oncologist, assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute
Laura J. Chambers, DO
Domenica Lorusso, MD, PhD
Domenica Lorusso, MD, PhD
Domenica Lorusso, MD, PhD
Laura J. Chambers, DO
Angeles A. Secord, MD, MHSc
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.